- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04882345
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE)
Evaluate the Safety and Efficacy of Almonertinib in the Treatment of Advanced NSCLC Patients With EGFR-sensitive Mutations Who Are Safety Intolerant After Osimertinib Treatment: a Prospective, Multi-center, Single-arm Clinical Trial
연구 개요
상세 설명
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Shun Lu, Doctor
- 전화번호: 13601813062
- 이메일: shun_lu@hotmail.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Over 18 years old (including 18 years old) and under 75 years old (including 75 years old)
- Histologically or cytologically diagnosed as locally advanced or metastatic NSCLC.
- The CTCAE ≥ grade 3 AE related to osimertinib treatment in previous treatment with osimertinib, or platelet count <75×109 / L (≥CTCAE grade 2), white blood cell count <3×109 / L (≥ CTCAE grade 2), total bilirubin> 1.5×ULN (≥CTCAE grade 2), transaminase (ALT/AST)>3.0×ULN (≥CTCAE grade 2), and the toxic reaction has been alleviated or restored to ≤CTCAE grade 1 patient.
- Tumor tissue samples diagnosed as locally advanced or metastatic NSCLC are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations). If the tumor tissue is accessible, it is recommended to send the tumor tissue for examination; if the tumor tissue is not accessible or the patient cannot accept a tissue biopsy, a blood sample is also acceptable.
- The Eastern Cooperative Oncology Group (ECOG) physical status score is 0 to 1, and it has not deteriorated in the previous 2 weeks, and the minimum expected survival is 12 weeks.
- The patient has at least one tumor lesion that can be accurately measured at baseline, and the longest diameter at baseline is ≥10 mm (if it is a lymph node, the short diameter is required to be ≥15 mm). The selected measurement method is suitable for accurate repeat measurement, which can be computed tomography (CT) or magnetic resonance scan (MRI). If there is only one measurable lesion, it can be accepted as the target lesion, and a baseline assessment of the tumor lesion should be performed at least 14 days after the diagnostic biopsy.
Women of childbearing age should take appropriate contraceptive measures from screening to 3 months after stopping the study treatment and should not breastfeed. Before starting the administration, the pregnancy test is negative, or meeting one of the following criteria proves that there is no risk of pregnancy:
- Postmenopausal is defined as amenorrhea for at least 12 months after the age is greater than 50 years and all exogenous hormone replacement therapy is stopped.
- For women younger than 50 years old, if the amenorrhea is 12 months or more after stopping all exogenous hormone treatments, and the luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels are within the laboratory postmenopausal reference value range, also It can be considered post-menopausal.
- Have received irreversible sterilization, including hysterectomy, bilateral ovariectomy or bilateral fallopian tube resection, except for bilateral fallopian tube ligation.
- Male patients should use barrier contraception (i.e. condoms) from screening to 3 months after stopping the study treatment.
- The subjects themselves participated voluntarily and signed an informed consent form in writing.
Exclusion Criteria:
Have received any of the following treatments:
- Have previously received any EGFR tyrosine kinase inhibitor treatment except osimertinib;
- The patient had undergone major surgery within 4 weeks before the first administration;
- Accept other test drugs, and within 5 half-lives;
- Within 7 days before the first administration of the study drug, CYP3A4 strong inhibitors, inducers, or drugs with a narrow therapeutic window that are CYP3A4 sensitive substrates have been used.
- Patients with other malignant tumors who need standard treatment or major surgery within 2 years after the first administration of the study treatment.
- As judged by the investigator, there are any serious or poorly controlled systemic diseases, such as poorly controlled hypertension, active bleeding-prone constitution, or active infection. No need to check for chronic diseases.
- Refractory nausea, vomiting or chronic gastrointestinal disease, inability to swallow study drugs or having undergone extensive bowel resection may affect the full absorption of Almonertinib.
- A history of interstitial lung disease, a history of drug-induced interstitial lung disease, a history of interstitial pneumonia requiring steroid therapy, or any evidence of clinically active interstitial lung disease.
Meet any of the following cardiac examination results:
- The average corrected QT interval (QTc)> 470 msec obtained from 3 ECG examinations in the resting state, the Fridericia formula is used for QT interval correction (QTcF);
- Resting ECG suggests that there are various clinically significant rhythms, conduction or ECG morphological abnormalities (such as complete left bundle branch block, 3 degree atrioventricular block, 2 degree atrioventricular block, and PR between Period> 250 msec);
- There are any factors that increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death or prolonged QT of immediate family members under 40 Any concomitant drugs in the interval;
- Left ventricular ejection fraction (LVEF) ≤50%.
Insufficient bone marrow reserve or organ function, reaching the following laboratory limits:
- Absolute neutrophil count <1.5×109 / L;
- Platelet count <100×109 / L;
- Hemoglobin <90 g/L (<9 g/dL);
- Alanine aminotransferase> 2.5 times the upper limit of normal (ULN)
- Aspartate aminotransferase> 2.5×ULN
- Total bilirubin> 1.5×ULN; or Gilbert syndrome (unconjugated hyperbilirubinemia)
- Creatinine>1.5×ULN and creatinine clearance rate<50 mL/min (calculated by Cockcroft-Gault formula); only when creatinine>1.5×ULN, creatinine clearance rate needs to be confirmed.
- Women who are breastfeeding or whose blood or urine pregnancy test results are positive within 3 days before the first dose of study treatment.
- Active fungal, bacterial and/or viral infections requiring systemic treatment.
- Have a history of hypersensitivity to any active or inactive ingredients of Almonertinib or to drugs with similar chemical structure to Almonertinib or the same class of Almonertinib.
- Any serious or uncontrolled eye disease may increase the safety risk of the patient as judged by the doctor.
- Patients who are judged by the investigator who may not comply well with the procedures and requirements of the study.
- The investigator judges that there are any patients with conditions that endanger the safety of the patient or interfere with the evaluation of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Almonertinib group
Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
|
Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations. Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Assess the safety of Almonertinib: Number of AEs/SAEs
기간: Continuously throughout the study until 28 days after Termination of the treatment
|
Number of adverse events (AEs)/serious adverse events (SAEs)
|
Continuously throughout the study until 28 days after Termination of the treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Assess the anti-tumor activity: Progression Free Survival (PFS)
기간: From date of baseline until the date of disease progression or discontinuation from study, assessed up to 24 months
|
To assess the efficacy of Almonertinib in the treatment of advanced NSCLC patients with EGFR-sensitive mutations who are intolerant to safety after osimertinib treatment by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months. |
From date of baseline until the date of disease progression or discontinuation from study, assessed up to 24 months
|
Assess the anti-tumor activity: Objective response rate (ORR)
기간: From date of baseline until the date of disease progression or discontinuation from study, assessed up to 24 months
|
ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression assessed up to 24 months.
|
From date of baseline until the date of disease progression or discontinuation from study, assessed up to 24 months
|
Assess the anti-tumor activity: Disease control rate (DCR)
기간: From date of baseline until the date of disease progression or discontinuation from study, assessed up to 24 months
|
The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD assessed up to 24 months.
|
From date of baseline until the date of disease progression or discontinuation from study, assessed up to 24 months
|
Assess the anti-tumor activity: Duration of response (DoR)
기간: the time from date of documented progression or death in the absence of disease progression assessed up to 24 months.
|
DoR is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression assessed up to 24 months.
|
the time from date of documented progression or death in the absence of disease progression assessed up to 24 months.
|
Assess the anti-tumor activity: Overall survival (OS)
기간: an average of 4 years
|
Start of study drug to Survival Endpoint through study completion, an average of 4 years.
|
an average of 4 years
|
Assess the anti-tumor activity: Depth of Remission (DepOR)
기간: through study completion, an average of 1 year
|
The depth of remission (change in tumor size) refers to the amount of change in the sum of the length of the longest diameter of the target lesion defined by RECIST 1.1 when no new lesions appear or no non-target lesions have progressed compared with the baseline.
|
through study completion, an average of 1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Meiqi Shi, Jiangsu Cancer Institute & Hospital
- 수석 연구원: Yongsheng Li, The Affiliated Cancer Hospital of Chongqing University
- 수석 연구원: Jianying Zhou, Zhejiang University
- 수석 연구원: Xiuyu Cai, Sun Yat-sen University
- 수석 연구원: Yueyin Pan, The First Affiliated Hospital of University of Science and Technology of China
- 수석 연구원: Wenxiu Yao, Sichuan Cancer Hospital and Research Institute
- 수석 연구원: Chun Huang, Tianjin Cancer Hospital
- 수석 연구원: Minglei Zhuo, Peking University Cancer Hospital & Institute
- 수석 연구원: Conghua Xie, Wuhan University
- 수석 연구원: Qibin Song, Hubei Provincial People's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- YX-L-202109
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
폐암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
Almonertinib에 대한 임상 시험
-
Guangdong Association of Clinical TrialsJiangsu Hansoh Pharmaceutical Co., Ltd.모병
-
Cancer Institute and Hospital, Chinese Academy...아직 모집하지 않음비소세포폐암 | ERBB2 돌연변이 관련 종양 | 디시타맙 베도틴 | ERBB2 유전자 복제
-
Tian XieLinkDoc Technology (Beijing) Co. Ltd.모병